Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose subcutaneous methylnaltrexone for opioid-induced constipation in adults with advanced illness
2007-000854-30Phase 4Terminated
- Sponsor
- Salix Pharmaceuticals
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Methylnaltrexone bromide with Placebo (2 arms). Primary endpoint: Laxation response within 4 hours after at least 2 of the first 4 doses. Started Mar 2008; status: terminated.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2007-000854-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000854-30.